West Pharmaceutical Services, Inc. News
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
see moreWest Pharmaceutical Services, Inc. Market News
8d
West Pharmaceutical Services Reports Q2 2026 Earnings and Leadership Transition
- West Pharmaceutical Services announces Q2 2026 earnings and CEO transition.
9d
West Pharmaceutical Services Reports Q2 2026 Earnings Amid Market Volatility
West Pharmaceutical Services announces Q2 2026 earnings amidst stock decline.
16d
West Pharmaceutical Services to Release Q2 2026 Financial Results Amidst Strategic Developments
West Pharmaceutical Services to announce Q2 2026 results on July 23, 2026.
23d
West Pharmaceutical Services Faces Operational Challenges Amid Cyberattack
West Pharmaceutical Services reports operational disruptions due to a recent cyberattack.
29d
West Pharmaceutical Services Recovers from Cyberattack, Maintains Strong Financial Outlook
West Pharmaceutical Services restores operations post-cyberattack, affirms 2026 financial guidance.
05 May at 15:00
WST Q1 Beat Spurs GLP-1 Growth, Dublin Gains! YTD.
West Pharmaceutical (WST) delivered a strong Q1 beat with $844.9M in sales and $2.13 adjusted EPS, raised 2026 guidance, and highlighted GLP‑1 demand, Annex 1 conversions, and the new Dublin contract-services facility as key growth drivers while executing a sizable buyback.
17 Mar at 14:53
WST Rally: $1B Buyback, Q4 Beats & 2026 Upbeat Now
West Pharmaceutical Services (WST) strengthened its shareholder case this week with a $1 billion open buyback, a maintained quarterly dividend and Q4 results that topped expectations. Management’s 2026 guidance, operational fixes and strategic moves around HVP and GLP‑1 exposure support the stock’s near‑term momentum, while execution risks warrant monitoring.